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Abstract
Chronic wounds are wounds, which failed healing and timely reparative process to pro-
duce anatomic and functional integrity over a period of 3 months. New physical therapy 
for chronic wounds is extracorporeal shock wave therapy (ESWT). ESWT generators can 
be focused, defocused, and radial. ESWT is non-invasiveness, low-associated complication 
rates, efficacy for indications refractory to other standards of practice, and cost-effectiveness. 
ESWT determines mechanotransduction that is possible as most of the cells of the body, 
thank to surface receptors and other transmission signals. In the specific field of ESWT, 
different biochemical substances are able to influence the processes of different cell lin-
eages, besides to induce the formation of new small blood vessels. So, ESWT enhanced cell 
proliferation at the local wound tissue level, stimulated extracellular matrix metabolism, 
decreased apoptosis, and downregulated oxygen-mediated burst of leukocytes, probably 
stimulating homing and differentiation of stem cells with high tissue regenerating poten-
tial. From numerous experimental and clinical data, it is possible to conclude that ESWT 
would improve not only the wounds healing process but also the regeneration events.
Keywords: extracorporeal shock wave therapy, wound healing, chronic wound, 
regenerative medicine
1. Introduction
Chronic wounds are defined as wounds, which failed healing and timely reparative process 
to produce anatomic and functional integrity over a period of 3 months [1].
All wounds beyond their  etiological  origin  such as venous or arterial insufficiency or dia-
betes can be potentially chronic. The transition from an acute to a chronic wound injury can 
occur at any stage of his recovery [2–4].
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical treatment includes wound bed preparation with surgical and nonsurgical debride-
ment [5], application of specialized dressings providing the wound with a moist environment 
[6], and medical or surgical intervention to achieve adequate vascular inflow and outflow 
and sufficient offloading to avoid pressure necrosis [7]. A relatively new physical therapy 
application for chronic wounds is represented by extracorporeal shock wave therapy (ESWT) 
[8]. Other approaches include hyperbaric oxygen therapy (HBOT) [9, 10], vacuum-assisted 
wound closure [11–13], low level laser therapy [14, 15], and electrical stimulation [16].
2. ESWT and chronic wound healing
Nowadays, in clinical practice, three different types of ESW generators are available, equipped 
with different types of sources, and they can also be differentiated as: focused, defocused, and 
radial. Focused ESWT is generated by electromagnetic, electro-hydraulic, and piezoelectric 
sources [17–20].
Pressure pulses rise rapidly in the range of 10–100 MegaPascal Pressure (MPa) and concen-
trate the acoustic energy beam with a penetration depth of approximately 12 cm. A metallic 
half-ellipsoid-shape reflector focused the almost spherical acoustic waves, which has been 
generated in the first focal point of ellipsoid directly to a second focal pit that is the therapeu-
tic target [21, 22].
ESWT defocused produces an acoustic planar wave, generated by electromagnetic and elec-
trohydraulic devices. These applicators use a parabolic reflector that generates a parallel wave 
with a diameter size of the reflector in order to apply the shock waves to a larger area [23, 24]. 
Radial waves (rSW) are a low-to-medium-energy shock wave (less than 0.1 mJ/mm2) generated 
through the acceleration of a projectile pneumatically propelled inside a barrel in the handpiece 
of the device. The high kinetic energy is transferred directly to the skin, on which the applicator 
is directly placed, and then transmitted radially (hence the expression “radial waves”) to the 
target zone [25], scattering and dampening by the third power of the penetration depth in the 
tissue while deepening up to 3.5 cm, without focusing the shock wave field in the tissue.
Compared with the conventional focused shock wave—whose focus is centered on the target 
site instead of on the tip of the applicator and whose wave shows a higher peak and a very 
short rise in pressure—the radial shock wave differs for the centering of the focus (placed on 
the tip of the applicator instead of on the target site) and the shape of the waves themselves 
(showing a lower peak pressure and a very long rise), and the propagation is limited to the 
most superficial (but larger) areas of the body [26].
3. ESWT and basic science: mechanotransduction and modulation of 
gene transcription
Therapeutic efficacy of low-energy defocused ESWT on delayed healing or chronic wounds 
has been demonstrated in experimental studies and clinical trials [27]. Advantages of ESWT, 
Physical Therapy Effectiveness228
compared with other therapeutic interventions, include non-invasiveness, associated com-
plication rates, efficacy of indications refractory to other standards of practice, and cost-
effectiveness [28].
ESWT determines the mechanotransduction that is a complex process characterized by sev-
eral steps: (1) transduction of mechanical forces in receptors detected by signals on cells, (2) 
conversion of mechanical signal into electrical and biochemical messages for obtaining a cel-
lular response, cytoplasmic level, (3) transfer of a signal from the sensor to effectors molecules, 
in nucleus, and finally (4) biological changes determined by gene activation. It is a biological 
mechanism that involves numerous cells and organs [29–31]: for example, endothelial cells 
respond to shear stress stimulation, but also others as tenocytes, bone cells, and fibroblasts.
ESWT induces production of different biochemical substances that are able to influence the pro-
cesses of different cell lineages, besides to induce the formation of new small blood vessels [32].
In fact, a lot of studies showed how ESWT is effective in stimulating several endogenous 
growth factors such as epidermal growth factor, insulin-like growth factor 1, vascular endo-
thelial growth factor (VEGF), and (nitric oxide) NO production, inducing angiogenesis and 
promoting the healing of tendons, muscles, cartilage, bone and skin, fractures, ulcers, and 
complex lesions [33, 34].
Angiogenesis is one of the basic conditions for supporting healing processes in the different 
affected tissues. Structural mechanical stress, induced by ESWT changes in cytoskeleton and 
increase in NOS activity and VEGF-A expression, acts as an angiogenesis process. Furthermore 
in vitro, it modulates the release of anti-inflammatory cytokine (IL1, IL-6, and IL10) and trans-
forming growth factor 1TGF1-VEGF, that promote the migration of macrophages, fibroblasts, 
and epithelial cells, enhancing collagen deposition into the damaged area [35–40].
Furthermore, if applied in multiple ESWT treatments, it was possible to obtain active deg-
radation of the fibrous abnormal tissues, thanks to a synergistic modifications in pro- and 
anti-fibrotic proteins (TGF-β1 and matrix metalloproteinase 2, respectively), thus underlining 
a possible role in fibrotic tissue reabsorption/remodeling [41, 42].
ESWT influences the toll-like receptor 3 (TLR3) pathway [43], which plays a fundamental role 
in pathogen recognition and activation of innate immunity, so ESWT modulates the inflam-
matory responses related to immunology pathway [44–49].
The most recent and relevant ESWT evidence is the effect on modulation of gene expression, 
thus increasing the possibility of a regenerative action.
In animal models, ESWT has been shown to produce favorable molecular microenviron-
ment in the wound tissue, suppress early pro-inflammatory cytokines and chemokines, and 
enhance expression of several wound healing relevant genes [46, 50, 51].
ESWT increases the Platelet-Cell Adhesion Molecule-1 (PECAM-1) production on leukocytes 
and on endothelial cells, which mediate a physical link between the cell surface and the 
nuclear envelope, and it is critically involved in the trans-endothelial migration processes 
at inflammatory sites, endothelial cell migration, and formation of new blood vessels. This 
may transmit mechanical or biochemical signals that may modulate the genetic expression 
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of cells [50, 52]. Furthermore, PECAM-1 is not only involved in cell adhesion but also is inti-
mately involved in signaling, for example, by binding and modulating nuclear/cytoplasmatic 
β catenin localization. At the membrane, β-catenin forms complexes with E-cadherin to gen-
erate cell adhesion complexes responsible for maintaining the structural integrity of many 
epithelial tissues. On the other hand, accumulation of β-catenin in the nucleus, in response to 
Wnt signaling pathways (a group of signal transduction pathways, made of proteins that pass 
signals into a cell through cell surface receptors), facilitates complex formation with T cell-
specific (TCF) transcription factors. TCF leads to activation of a genetic program influencing a 
range of cellular processes, as cell growth and cell movement [53, 54] (Figure 1).
ESWT indirect effect on modulation of gene transcription has been found to include expression 
of c-Myc gene, regulation of metalloproteinase matrilysin (the smallest member of metallopro-
teinase enzymes), modulation of the activating protein-1 (AP-1) transcription complex, particu-
larly cc-Jun and Fra-1 components that are essential for MMP-1 gene expression, urokinase-type 
plasminogen activator receptor, zonula occludens-1 (ZO-1) protein, and cyclin D1 [55].
In vivo shock wave treatment increases Ras-dependent superoxide, which in turn regulated 
cytosolic extracellular regulated kinase (ERK) phosphorylation and hypoxia-inducible factor-
1a transactivation, which is considered as the master transcriptional regulator of cellular and 
developmental response to hypoxia [56].
ESWT treatment upregulates expression of cell nuclear antigen (PCNA), which is important 
for both DNA synthesis and repair; furthermore, it increases TGF genes (mRNA) [57].
TGF α is predominantly expressed in keratinocytes and has a profound autocrine mitogenic 
effect on keratinocytes, augments angiogenesis in wound healing, and it is upregulated in 
keratinocytes after skin injuries; TGFβ 1 mRNA shows higher values in ESW-treated fibro-
blasts, relating to increased expression of VEGF and endothelial NOS (eNOS), also known as 
constitutive NOS (cNOS), as well as genes encoding collagens types I and III [58, 59].
Shock wave treatment is capable of inducing an increase of activated fibroblasts, CD34-
positive fibrocytes, and fXIIIa-positive dendritic cells; this process is thought to lead to the 
deposition of new collagen, characterized by thinner collagen fascicles and parallel orienta-
tion to the dermoepidermal junction. Additionally, ESWT may play a significant role in the 
increase in CD31-positive vessel density in the dermis allowing an improved tissue metabo-
lism [60]. In animal models, ESWT modulates expression of angiogenesis pathway-specific 
genes such as those encoding for ELR motif (glutamic acid-leucine-arginine sequence) posi-
tive (ELR + -CXC) chemokines, CC-chemokines, and cytokines [51].
In addition, shock wave exposure induces strong expression of stromal cell-derived mRNA 
factor 1, which influences medium induced chemo-attraction of CD34+ cells, hematopoietic 
stem cells, and the effect on bone marrow-derived mononuclear cells facilitating cell differen-
tiation to endothelial phenotype [61].
So, ESWT-enhanced cell proliferation at the local wound tissue level stimulated extracellu-
lar matrix metabolism, decreased apoptosis, and downregulated oxygen-mediated burst of 
leukocytes, probably stimulating homing and differentiation of stem cells with high tissue 
regenerating potential.
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4. ESWT in chronic wound: clinical studies
In the published literature, there are hypothesis-generating experimental data as well as clini-
cal observations that suggest a heretofore unproven systemic effect of ESWT.
Schaden et al. in 2007 [62] demonstrated safety and potential efficacy of electrohydraulic 
unfocused shock waves applied to acute and chronic wounds (33.3% acute and 66.7% chronic 
wounds) of various etiologies (post-traumatic, venous, pressure, and arterial wounds). A total 
of 208 patients were included in the study and treated with the unfocused electrohydraulic 
device (DermaGold). Each treatment was placed onto wound dressing applied: from 100 to 
1000 pulses were applied according to wound size (100 pulses/cm2) initially, weekly, and then 
biweekly. The study describes the complete reepithelialization of wounds in 75% patients: 
Figure 1. (a) Wnt signaling—“Off” In the absence of Wnt, β-catenin is phosphorylated, so transcriptional process is stopped 
(b) Wnt signaling—“On” In the presence of Wnt ligands, a signaling cascade is initiated. β-catenin accumulates in the 
cytoplasm and is free to translocate into the nucleus where it acts as transcriptional coactivator of transcriptional factors of the 
TCF/LEF family. Modified from: https://www.sigmaaldrich.com/technical-documents/articles/biology/wnt-b-catenin.html.
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significant association was found between complete epithelialization and wound size (wounds 
<10 cm2 healed in 81.0 vs. 61.8% for wounds >10 cm2) as well as between complete healing 
and wound duration (wounds persisting >1 month showed 57.1% healing rate vs. wounds 
<1 month that had a healing rate of 83%). With regard to wound etiology, venous stasis ulcers 
showed the lowest healing rates (36%), whereas all other wound etiologies showed at least 
a healing rate of 66% (arterial insufficiency ulcer—66.7%, decubital ulcer—71.4%, disturbed 
healing wounds—75.6%, posttraumatic tissue necrosis—86.6%, and burn wounds—100%).
Application of high energy unfocused shock waves for difficult wounds was confirmed by a 
work carried out by Saggini et al. [63]. In this study, 30 patients affected by chronic ulcers in the 
lower limb from more than 3 months that were unresponsive to conservative or advanced dress-
ing treatments or mechanical debridement were included. A group of 10 consecutive patients, 
randomly recruited, with chronic ulcers in the lower limb treated on the basis of regular con-
servative dressings have been used as a control group. Electrohydraulic unfocused ESWT treat-
ment consisted of 100 impulses at 0.037 mJ/mm2 each per cm2 of the row wound area (Evotron). 
The focal volume of the hand handled probes was 10–15 mm in diameter, and the total energy 
applied for each impulse was 3.5 mJ, with a frequency of 4 Hz or 240 impulses/minute. At the end 
of the study period, 16 ulcers healed completely (50%). Every patient underwent single sessions 
every 2 weeks, with a minimum of four and a maximum of 10 sessions for a complete treatment.
The wounds were classified on the basis of the location, width (cm), length (cm), row surface 
area (cm2), percentage of granulation tissue, percentage of fibrin tissue or necrotic tissue, pres-
ence of exudates, bacterial colonization (positive culture swabs or tissue scrapings), and pain.
Presence of exudates was determined as: none, minimal, moderate, and heavy, adapted 
from the wound bed preparation score developed by Falanga [64]. Complete healing was 
documented within the first four to six sessions. In all of the wounds, the amount of exudates 
decreased considerably, and the increasing percentage of granulation tissue compared with 
the fibrin/necrotic tissue was statistically significant. At the end of the study period, in the 
non-healed ulcers, a considerable improvement in the wound bed blood supply was docu-
mented. Improvement of all these parameters was noted within the first four to six sessions.
Wang et al. [65] included 74 patients with diabetic skin ulcers of the foot for comparing 
ESWT and hyperbaric oxygen therapy (HBOT). They were randomly divided into two 
groups (38 subjects in each group). ESWT, electrohydraulic focused, protocol provides two 
sessions for 6 weeks (300 + 100 pulses/cm2 at an energy flux density of 0.11 mJ/mm2). The 
HBOT was performed five times a week for a total of 20 treatments using a sealed multiplace 
chamber at a pressure of 2.5 atmospheres for 90 minutes total (25-minute sessions with 5- 
minute breaks). Post-treatment wound care was the same in both groups. Outcome variables 
included clinical assessment of the ulcers with photo documentation, blood flow perfusion 
scan, bacteriological examination, histological study, and immune-histochemical analysis. In 
ESWT group, results showed a significant increase of eNOS, VEFG, and proliferation cell 
nuclear antigen (PCNA) and a decrease of terminal deoxynucleotidyl transferase-mediated 
UTP nick end labeling (TUNEL) with reduction of apoptotic phenomena. It reported signifi-
cant improvement in local blood perfusion in the participants that had DFU and treated with 
ESWT (0.61, P < 0.002) compared with those treated with HBOT (0.50). Complete ulcer healing 
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was found in 31% of the ESWT group compared with 22% of the HBOT group. Furthermore, 
in more than 50% was observed a reduction of wound surface and was observed in 89% of 
shock wave-treated ulcers compared with 72% of HBOT-treated ulcers. They concluded that 
ESWT of chronic diabetic foot ulcer is superior to HBOT, and it appears that ESWT results in 
increased angiogenesis and cellular events consistent with decreased cell apoptosis.
Other scientific literature, Wang et al. [66], confirmed that ESWT appeared to be more effective 
than HBOT for treatment of chronic wound, in a prospective open-label, randomized, but not 
blinded study. Patients were randomly divided into two groups: the ESWT, group consisted 
of 39 patients with total of 44 chronic diabetic foot ulcers, while the HBOT group consisted 
of 38 patients and 40 foot ulcers. ESWT treatment was carried out with an electrohydraulic-
unfocused device, derma PACE device, and the dosage was ulcer size dependent with the 
numbers of impulses equal to the treatment area in cm2× 8, with a minimum of 500 impulses 
at energy setting E2 (equivalent to 0.23 mJ/mm2 energy flux density) at a rate of 4 shocks per 
second twice per week for a total of six treatments. The HBOT group received hyperbaric was 
performed with patients in a sealed multi-place chamber at a pressure of 2.5 atmospheres 
absolute daily for a total of 20 treatments. The assessment, at 3 and 6 weeks, then once every 
3 months, was carried out by local blood flow perfusion scan and histopathological examina-
tion after biopsy specimens. Clinical assessment of the ulcer status was performed by physical 
examination including visual observation and photo-documentation.
Clinical results showed completely healed ulcers in 57 and 25% (P = 0.003); ≥50% improved 
ulcers in 32 and 15% (P = 0.071); unchanged ulcers in 11 and 60% (P < 0.001), and none wors-
ened for the ESWT and the HBOT group, respectively. Another interesting observation was 
that even though prior to study-based treatment levels of oxygenation were comparable, 
oxygenation levels were significantly higher after shockwave therapy than after HBOT 
(P = 0.002). In histopathological examination, the ESWT group showed considerable increases 
in cell proliferation, cell concentration, and cell activity and a decrease in cell apoptosis as 
compared to the HBOT group.
Moretti et al. [67] evaluate the effect of ESWT in 30 patients affected by neuropathic diabetic 
foot ulcers. One group was treated with standard care and ESWT with an focused electromag-
netic device, three sessions (every 72 hours), with 100 pulses per 1 cm2 of wound delivered 
at each session at a flux density of 0.03 mJ/mm2; while the control group was treated with 
only standard care. The wound area and its following reductions were measured with the 
Rhinoceros program running and the reepithelialization was measured as the time to com-
plete ulcer healing was measured as the number of days from the start of treatment to the date 
in which each patient achieved complete wound healing. If the healing did not occur within 
the 20 weeks of the study, the patient was considered to be non-healing. The proportions of 
ulcers that healed in 20 weeks in the A and B groups were 53.33 and 33.33%, respectively. For 
the ulcers that healed during the 20-week period, the healing times were 60.8 ± 4.7 days (mean 
± DS) in group A and 82.2 ± 4.7 days (mean ± DS) in group B patients (P < 0.001). A significant 
difference was observed in the index of the re-epithelization between the two groups, with 
values of 2.97 ± 0.34 mm2/die (mean ± DS) in the ESWT group and 1.30 ± 0.26 mm2/die (mean ± 
DS) in the control group (P < 0.001). Both the healing rate and the healing time were increased 
in the ESWT group, and the differences were statistically significant.
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Larking et al. [68] investigated the response to ESWT of pressure ulcers in a randomized, 
placebo-controlled crossover study. All patients included in the study were patients with 
disabilities, presenting pressure ulcers for more than 3 months in different anatomical sites. 
The protocol consisted of a 3-week baseline observation period to confirm stable wound 
conditions, and subsequently, ulcers were allocated randomly to ESWT or placebo group 
and followed-up for 4 weeks receiving treatment each week. After this 4-week period and a 
2-week washout period, study crossover to the other treatment ensued. Interestingly, regard-
less of which group they belonged to (initial treatment group or cross-over treatment group), 
all nine ulcers showed significant improvement (average of three measurements of ulceration 
was recorded) at 6–8 weeks after the initial shockwave treatment. This phenomenon was dis-
cussed as follows that shock waves may first determine debridement of the wounds receiving 
proper wound bed, which is then conditioned for healing.
Ottomann et al. in 2012 [69] performed a prospective randomized phase II trial of accelerated 
reepithelialization of superficial second-degree burn wounds using extracorporeal shock wave 
therapy. A total of 100 patients were included and then randomly assigned in two groups: 
control group received a standard treatment debridement of devitalized skin (epidermis) and 
topical antiseptic therapy and the experimental group received the standard treatment and 
a single application of defocused ESWT (100 impulses/cm at 0.1 mJ/mm) applied once to the 
study burn, after debridement. Patients receiving shock wave therapy showed significantly 
reduced mean time to complete (>95%) second-degree burn wound epithelialization (9.6 ± 1.7 
vs. 12.5 ± 2.2 days). The study concludes that application of a single defocused shock wave 
treatment to the superficial second-degree burn wound after debridement/topical antiseptic 
therapy significantly was able to accelerate healing.
Saggini et al. in 2013 [70] by a randomized, controlled trial, with blind assessment, assessed 
the efficacy of unfocused shock wave treatment in patients with diabetic ulcers, pressure 
ulcers, traumatic ulcers, and vascular ulcers, through the analysis of the percentage of wound 
healing (calculated as the reduction in wound area divided for the initial area percent), the 
antibacterial effect, through the evaluation of specific buffers and searching for possible 
occurrence of infection during therapy. A total of 124 patients with ulcers at least from 3 to 
24 months were treated with a frequency of 1 session every 7 days for 7 weeks. A total of 62 
subjects were included in Group A and treated with ESWT unfocused probe with Dermagold 
electrohydraulic system; the mean energy applied for each pulse in Group A was equal to 
0.10 mJ/mm2 per cm2 (0.09/0.11 mJ/mm2) with a total energy density equal to 1250 J. A total of 
62 subjects were included in Group B but 22 withdrawn, so 40 were treated with ESWT elec-
trohydraulic unfocused device (Evotron); the mean energy applied in Group B was equal to 
0.037 mJ/mm2 per cm2 with a total energy density equal to 462 J. In both Groups A and B were 
administered 300–600 impulses per session relating to the wound area at a frequency of 4 Hz 
or 240 pulses per minute. Results showed a reduction of 80% of mean area of wound in Group 
A: particularly, the 23 diabetic wounds in this group achieved a 85% mean decrease of the row 
surface area from a mean surface area of 1.45 cm2 to a final average surface area of 0.2 cm2; the 
10 pressure wounds demonstrated a 68% mean decrease of the row surface area rising from a 
mean surface area equal to 9.8 cm2 to a final surface area of 3.1 cm2. The 10 traumatic wounds 
obtained an 85% decrease of the row surface area rising from a mean surface area of 1 cm2 
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to a mean surface area of 0.15 cm2. Nineteen vascular wounds demonstrated a 76% decrease 
of the row surface area rising from a mean surface area of 2.75 cm2 to a mean surface area of 
0.65 cm2. At the end of protocol (7 weeks), 44 patients achieved complete wound healing, while 
the remaining 18 obtained a partial recovery. As for the pain, there was a 79% mean visual 
analogical scale (VAS) reduction. The mean surface area in Group B, equal to 3.4 cm2 at the 
beginning, decreased by 67%: diabetic wounds in this group achieved a 60% mean decrease of 
the row surface area rising from a mean surface area of 1.2 cm2 to a final average surface area 
of 0.48 cm2; traumatic wounds obtained an 85% decrease of the row surface area rising from 
a mean surface area of 1.2 cm2 to a mean surface area of 0.18 cm2; pressure wounds demon-
strated a 72% mean decrease of the row surface area rising from a mean surface area equal to 
8.8 cm2 to a final surface area of 2.5 cm2; vascular wounds demonstrated a 61% decrease of the 
row surface area rising from a mean surface area of 3.5 cm2 to a mean surface area of 1.37 cm2; 
as for wounds in patients with cryoglobulinemia was found a 33% decrease of the row surface 
area. At the end of therapy, 40% of patients had reached a completed healing, 37.5% a partially 
healed, and 22.5% unchanged. As for pain, in Group B, there was a 48% mean VAS reduction 
(2.7 reduction points compared to the initial value) with a final mean value equal to 3 (range 
1–6). No wound in Group B developed infection during therapy; such evidence may confirm 
and correlate to bactericidal effect of this system because of dejection of Staphylococcus aureus 
in culture swabs. Authors concluded that the greater improvement in Group A is linked to the 
higher total flux density of energy transferred from the probe, as regards the application time, 
a significant reduction in wound areas was observed after 7 weeks and a peak of increase 
of the results, in terms of wound size reduction, between the third and the fourth week of 
treatment, so therefore the time required to obtain the regenerative effects would be at least 
7 days between one.
Omar et al. [71] in a single blinded randomized controlled study included 35 patients with 
chronic diabetic foot ulcer. They assessed the efficacy of ESWT on the healing rate, wound 
surface area, and wound bed preparation. In experimental group (19 patients/24 ulcers), 
patients received ESWT with a pneumatic unfocused device, twice a week at a frequency 
of 100 pulse/cm2 and energy flux density of 0.11 mJ/cm2; all patients received standardized 
wound care consisting of debridement, blood-glucose control agents, and footwear modifica-
tion for pressure reduction.
Clinical outcome measures focused on wound surface area (WSA), the percentage of reduc-
tion in the WSA, rate of healing and wound bed preparation at baseline, after the end of the 
interventions (W8), and at 20-week follow-up (W20).
Results showed completely healed ulcers in 33.3 and 54% in ESWT-groups and 14.28 and 
28.5% in the control group after intervention (W8), and at follow-up (W20), respectively. 
The average healing time was significantly lower (64.5 ± 8.06 days vs. 81.17 ± 4.35 days, 
P < 0.05) in the ESWT-group compared with the control group. The authors concluded that 
ESWT-treated ulcers had a significant reduction in wound size and median time required 
for ulcer healing.
Nossair et al. [72] evaluated the effectiveness of shock wave therapy in enhancing diabetic 
wound healing. Forty patients with lower limb ulcerations were included in this study and 
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divided randomly into two groups: one treated with shock wave therapy (pneumatic unfo-
cused device) beside medications and traditional wound care methods (Group A), while the 
other treated with medical treatment and traditional wound care (Group B). The protocol 
consists of a course of three sessions (a session every 1 week for 12 weeks), with 500 pulses 
per 1 cm2 of wound delivered at each session at a flux density of 0.1 mJ/mm2; three sessions, 
one session every week.
The control group performed the essentials of foot ulcer care, namely debridement, adequate 
pressure relief, and treatment of infection. Assessments were made at baseline and after 
12 weeks as reducing wound surface area and epithelialization rate. After 12 weeks, there 
was significant decrease in the surface area of both group, and they become (1.92 ± 3.28) 
and (4.65 ± 3.43) for shock wave and control group, respectively. A significant difference 
was observed in the wound surface area and in the rate of epithelialization between both 
groups after 12 weeks. The rate of epithelialization for shock wave and control group were 
(83.26 ± ±27.43)% and (48.66 ± 31.68)%, respectively, (P <0.001). The results of this study 
revealed that there was a significant difference in wound surface area only after 12 weeks 
(post-treatment) of the treatment between in shock wave group and the control group 
(P = 0.0001).
Another scientific work [73] describes the safety and efficacy of ESWT in patients with 
non-healing diabetic foot ulcer of various etiologies such as peripheral arterial disease and 
neuropathy. Five patients received electromagnetic unfocused ESWT in 6–8 weekly sessions, 
delivered as 500 shocks at wound margin and 1000 shocks distal to the wound (lower leg), 
spread over the entire muscle area at a flux density of 0.25 mJ/mm2, using the Cactor hand 
piece of the Duolith SD1 device.
Clinical assessment was carried out 2 weeks after the final session of treatment. Wound area 
was measured using digital photography, pressure sensitivity was evaluated by the monofila-
ment test, and calculation of the ankle brachial index (ABI) was done at each visit.
After 6–8 weekly sessions of ESWT, a significant reduction in ulcer surface area was observed 
in four patients with a mean post-treatment ulcer size of 6.33 cm2 ± 5.00 (mean reduction: 
1.21 ± 0.82 cm2, P = 0.03).
All patients showed improvement in the ABI and monofilament test after treatment (mean 
ABI and monofilament test score of 0.9 ± 0.12, p value: 0.00 and 4/10 after treatment, respec-
tively). It is interesting that the increase of ABI in all patients after treatment confirms 
the strong angiogenic effect of ESWT leading to enhanced limb perfusion. The majority 
of clinical trials investigate the effectiveness of short-term ESWT, instead Wang et al. 
[74] evaluate the long-term effects of ESWT in chronic foot with 5-year follow-up; they 
included 38 patients with 40 ulcers in the diabetes mellitus (DM) group and 29 patients 
with 32 ulcers in the non-diabetes mellitus (non-DM) group. All patients received unfo-
cused ESWT with a derma PACE device, and dosage is ulcer size dependent. The number 
of pulses was calculated as follows: ¼ of the treatment area (cm2 × 8); but it had reach to 500 
shocks (4Hz-equivalent to 0.11 mJ/mm2 energy flow density) twice/week for six treatments. 
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The follow-up examinations were performed in 1, 3, 6, and 12 months and then once a year. 
The evaluations included clinical assessment of the ulcer status, including the size, shape, 
and depth with photo documentation, local blood flow perfusion scan, and the mortal-
ity and morbidity including the rates of amputation in 1 and 5 years after ESWT. Tissue 
viability was evaluated by local blood flow perfusion scan preoperatively and at 6 weeks, 
1 year, and 5 years postoperatively.
After ESWT, the blood flow perfusion rates significantly improved in both DM (P ¼ 0.011) and 
non-DM (P ¼ 0.033) groups. The improvements of blood flow perfusion rate began at 6 weeks 
and lasted for up to 1 year after ESWT. The blood perfusion rates significantly decreased in 
both groups from 1 to 5 years compared with the data before treatment, at 6 weeks (P ¼ 0.006) 
and 1 year (P < 0.001). The blood flow perfusion rate of the non-DM group is significantly 
better than that of the DM group from 1 to 5 years after ESWT (P ¼ 0.04).
The clinical outcomes, mortality, and morbidity were compared with a control data of 149 
patients with diabetic foot ulcers previously treated by the author. The experimental group 
shown a better overall clinical outcomes of healed and improved ulcers at 1 year (73 vs. 64.4%) 
compared with the historical controls, although the differences did not reach statistical sig-
nificance (P ¼ 0.338). The mortality rate was 9.4% in the historical controls and 0% at 1 year 
(P ¼ 0.044) and 24% at 5 years (P ¼ 0.017) in the experimental ESWT patients. The historical 
controls showed significantly higher amputation rates compared with the ESWT group at 1 
year (P < 0.001) and 5 years (P < 0.001) and more operations other than amputation than ESWT 
group the at 1 year (P ¼ 0.003) and at 5 years (P ¼ 0.010), respectively. At the conclusion of this 
study, Wang et al. concluded that ESWT appears effective in the treatment of chronic diabetic 
and non-diabetic foot ulcers. However, the effects of ESWT significantly decreased from 1 to 
5 years after treatment.
5. Discussion
The importance to describe current perspectives of management of soft tissue wounds is 
linked to the serious medical and social problem for which it stands, and the purpose of 
this narrative review is to evaluate evidence of effectiveness of ESWT on chronic wound and 
indicate an application guideline in relation to our experience [75, 76]. The primary goal in the 
treatment of soft tissue wounds is to produce beneficial stimuli in the tissue, which stimulate 
and support tissue repair and regeneration.
Modern wound bed preparation strategies are to applied immediate [77–79] and after 
the rational use of advanced wound care therapies when wounds do not respond suffi-
ciently to good standard care after 4 weeks or sooner as circumstances dictate: negative 
pressure wound therapy, HBOT, biophysical electrical stimulation, diathermy, pulsed 
electromagnetic fields, pulsed radiofrequency energy, and low-frequency non-contact 
ultrasound—MIST and ESWT [80]. The described ESWT studies revealed a lack of unifor-
mity classification of ulcers (etiology, grade, and size) and a variety of types and parameters 
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of treatment and the duration of ulcers varied across identified studies (1–24 months) or the 
initial ulcer size (1 cm2 up to 10 cm2); therefore, it is appropriated to group them based on 
measuring the therapeutic effect of ESWT. In this chapter review, the relevant clinical out-
comes were focused on wound healing and reepithelialization time. However, the meth-
ods used to define them are varied. The evidences have shown clinical efficacy as regards 
speed of healing highlighting the size of the wound. Furthermore, ESWT is a safe mode 
and associated with a low rate of complications during its application both short-term 
and medium-term periods of follow-up. All included studies provided sufficient details 
to allow the repetition of the intervention protocol. However, we can highlight differences 
in frequency, dosage, duration and the generator type, the duration of the protocols, and 
the device used. This heterogeneity of parameters can make difficult comparisons between 
studies with aim to standardize the application of ESWT in chronic ulcers. In many cited 
studies, the number of pulses in a single ESWT session ranged from 10 to 500 pulses/cm2 
(206.4 ± 172.3 pulses/cm2), but the most frequent value was 100 pulses/cm2 of wound area. 
Not all studies did describe frequency parameters which instead can be considered impor-
tant in order to evaluate the application and effects of ESWT. According to the review of 
clinical research studies, in the case of chronic wounds, ESWT sessions were typically once 
or twice per week, as well as once every 2 weeks. The total number of treatment sessions 
ranged between three and six. The average time of a single ESWT session was 1–3 minutes, 
depending on the size of the wound.
So, ESWT represents a new application of translational medicine and a current border 
not only as an advanced physical therapy but also as a regenerative application [81]. This 
regenerative potential is linked to mechanotransduction, thanks to cytoplasmic cellular 
and extracellular cascade [82], that generates a gene expression modulation. This com-
plex biological phenomenon determines a change in the key factors of regenerative skin 
process.
In fact, ESWT can reduce expression of several metalloproteinases and interleukins (MMPs 
and ILs) [83]; it stimulates proliferation and collagen synthesis, mediated by early up- 
regulation of proliferating cell nuclear antigen (PCNA) and TGF-beta1 gene expression, 
endogenous NO release and synthesis and TGFbeta1 protein and then collagen synthesis 
[84]; in vitro it improves functional activities of ruptured tendon-derived tenocytes (prolifera-
tion and migration), which could probably contribute to tendon healing in vivo [85]; it can 
enhance osteogenic differentiation of mesenchymal stem cells, through superoxide-mediated 
signal transduction [86]; furthermore, the ESWT facilitates the regeneration process of the soft 
tissues by early expression of angiogenesis-related growth factors [87–90].
In addition, shock wave exposure induces strong expression of stromal cell-derived mRNA 
factor 1, which influences medium induced chemoattraction of CD34+ cells and hematopoi-
etic stem cells, and the effect on bone marrow-derived mononuclear cells facilitates cell differ-
entiation to endothelial phenotype. These molecular effects and gene expression are reflected 
in positive clinic results [8]. All this reduces the health and social costs.
Considering all this evidences, I could recommend for treatment chronic ulcers unfocused 
ESWT with fractionated energy in 2 weekly steps, because in this way, there is greater regen-
erative activation.
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6. Conclusion
From these experimental and clinical data, it is possible to conclude that ESWT would improve 
not only the wound healing process, but also the regeneration events. The knowledge rela-
tive to the mechanotransduction has had over the years a consolidation process, instead the 
modulation of gene transcription related to the regenerative processes on the treatment of 
chronic ulcers can be considered as a new border for other clinical studies and clinical trials.
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